JustPaste.it

"Neuroblastoma Therapeutics Market Poised to Grow at a CAGR of 6.9% by 2031"

neuroblastomatherapeutics.jpg


Neuroblastoma is a rare type of cancer that affects nerve cells and arises in early stages of development in the adrenal glands or nervous system. Neuroblastoma therapeutics are medications used to treat neuroblastoma and help relieve symptoms. The global neuroblastoma therapeutics market is primarily driven by the increasing incidence of pediatric cancers and rising demand for effective treatment options. Standard treatment options include chemotherapy, surgery, radiation therapy, stem cell transplants, immunotherapy, and tumor biology-based therapies.

The Global Neuroblastoma Therapeutic Market is estimated to be valued at US$ 2.78 Billion in 2024 and is expected to exhibit a CAGR of 6.9% over the forecast period from 2024 to 2031.

Chemotherapy drugs dominate the market as first-line therapy due to their effectiveness in treating high-risk neuroblastoma. However, targeted therapies and immunotherapies are exhibiting high growth as they help improve event-free survival and overall survival for high-risk patients with fewer side effects.

Key Takeaways
Key players operating in the neuroblastoma therapeutics market are United Therapeutics, Apeiron Biologics AG, AbbVie Inc., Boston Pharmaceuticals, and Bellicum Pharmaceuticals. United Therapeutics dominates with its product Unituxin (dinutuximab) approved for high-risk neuroblastoma.

The growing demand for effective neuroblastoma treatment options is a major driver for market growth. According to the American Cancer Society, an estimated 800 new cases of neuroblastoma are diagnosed in the United States each year, with high unmet needs in relapse/refractory neuroblastoma patients. The disease has a higher prevalence in children below 5 years of age.

The market is witnessing increased global expansion as key players focus on product development and commercialization in emerging Asian and Latin American markets. For example, Apeiron Biologics commenced a registration trial of APN401 in China in 2019 to meet the growing demand. Initiatives to spread awareness and improve early diagnosis also support market growth in developing regions.

Market Key Trends
A key trend in the neuroblastoma therapeutics market is the development of novel targeted therapies and immunotherapies. Several targeted drugs blocking critical pathways in neuroblastoma such as ALK, MET, RET, GD2, and CD47 are under evaluation. Recent FDA approvals of Besponsa (inotuzumab ozogamicin) and Lumoxiti (moxetumomab pasudotox-tdfk) have provided new treatment options. CAR T-cell therapies show promise, with encouraging responses observed in early clinical trials. Combination therapies leveraging different mechanisms are also emerging as an effective approach to further improve outcomes. Overall, the focus on precision and personalized medicine offers potential for better management of this high-risk pediatric cancer.


Porter’s Analysis
Threat of new entrants:
High capital requirement and regulatory barriers make entry difficult in this market.
Bargaining power of buyers: Buyers have moderate bargaining power. Developing economies have cost-sensitive buyers.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to differentiated products and technologies in this specialized market.
Threat of new substitutes: Threat of substitutes is low as neuroblastoma is life-threatening cancer requiring targeted treatment modalities.
Competitive rivalry: Intense competition exists among major players to develop novel products. Players differ based on product portfolios and regions of expertise.

The geographical region where the neuroblastoma therapeutic market is concentrated in terms of value is North America. The United States holds majority of the market share due to high healthcare spending and reimbursement. North America is estimated to account for around 35% of the global market value in 2024.

Asia Pacific region is expected to grow at the fastest rate during the forecast period from 2024 to 2031. Increasing patient population, rising healthcare spending, and growing awareness are driving the market in Asia Pacific countries like China and India. China is poised to become one of the most lucrative markets due to growing economy and improving access to healthcare.

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)